And many patients who wind up with the label of bipolar disorder are initially misdiagnosed with unipolar depression. Misdiagnosed patients like Ola often look back on years of worsening symptoms and ...

On January 20, 2026, the Food and Drug Administration's (FDA) new traceability rules — dubbed the Food Traceability Final ...

Some scientists say food dyes could make behavioral issues in children worse. Lawmakers in at least 10 states want to ...

Fall is in the air, and apple orchards are selling cinnamon donuts and apple cider. But health officials are warning that in ...

Collagen supplements are a popular anti-aging tool. Before you take them, here's everything you should know about what ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

Lawmakers passed a law designed to limit reproductive rights in Louisiana. But it may also limit patients’ chances of ...

Hundreds of Americans have jumped on a multi-state lawsuit alleging that the makers of Ozempic and Mounjaro caused ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...